Efficacy of intravitreal bevacizumab (Avastin™) for short-term treatment of diabetic macular edema

Journal of Medical Investigation

Volumn 56, Issue 3-4, 2009, Pages 111-115

  Nagasawa, Toshihiko ^a   Naito, Takeshi ^a   Matsushita, Shingo ^a   Sato, Hiroyuki ^a   Katome, Takashi ^a   Shiota, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Avastin; Bevacizumab; Diabetic macular edema; Diabetic retinopathy

Indexed keywords

BEVACIZUMAB; GLYCOSYLATED HEMOGLOBIN; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG EFFICACY; ENDOPHTHALMITIS; FEMALE; HUMAN; LASER COAGULATION; MALE; MEDICAL RECORD; OPTICAL COHERENCE TOMOGRAPHY; PHAKIC INTRAOCULAR LENS; PSEUDOPHAKIA; RECURRENT DISEASE; RETINA FOVEA; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY;

EID: 70350001619     PISSN: 13431420     EISSN: None     Source Type: Journal    
DOI: 10.2152/jmi.56.111     Document Type: Article

References (17)

1. Klein R, Klein BE, Moss SE, Moss SE, Cruickshanks KJ: The Wisconsin Epidemiologic Study of Diabetic, XVII: the 14-year incidence and progression of diabetic retinopathy and associated risk factors in type I diabetes. Ophthalmology 105: 1801-1815, 1998
2. Ferrara N, Hillan KJ, Gerber HP, Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3: 391-400, 2004
3. Spaide RF, Fisher YL: lntravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 26: 275-278, 2006
4. Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: lntravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 113: 363-372, 2006
5. Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, Sorenson J, Slakter JS, Freund KB, Cooney M, Fine HF: Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26: 279-284, 2006
6. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S: Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110: 1690-1696, 2003
7. Mohr S, Tang J, Kem TS: Caspase activation in retinas of diabetic and galactosemic mice and diabetic patients. Diabetes 51: 1172-1179, 2002
8. Bhavsar AR, Glassman AR, DRCRnet Group, SCORE Study Group: The risk of endophthalmitis fbllowing intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol 144: 454-456, 2007
9. Scott lU, Edwards AR, Back RW, Diabetic retinopathy clinical research network:. A phase ll randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114: 1860-1867, 2007
10. Ferrara N: Vascular endothelial growth fctor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004
11. Funatsu N, Yamashita H, Sakata K, Noma H, Mimura T, Suzuki M, Eguchi S, Hori S: Vitreous levels of vascular endothelial growth factor and intracellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology 112: 806-816, 2005
12. Rosenfeld PJ: Intravitreal Avastin: the low cost alternative to Lucentis? Am J Ophthalmol 142: 141-143, 2006
13. Gillies MC: What we don't know about Avastin might hurt us. Arch Ophthalmol 124: 1478-1479, 2006
14. Shahar J, Avery RL, Heilweil G, Barak A, Zemel E, Lewis GP, Johnson PT, Fisher SK, Perlman I, Loewenstein A: Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26: 262-269, 2006
15. Diabetic Retinopathy Clinical Research Network: Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 114: 525-536, 2007
16. Maia Jr OO, Takahashi BS, Costa RA, Scott IU, Tkahashi WY: Combined laser and lntravitreal triamcinolone for proliferative diabetic retinopathy and macular edema: one-year results of a randomized clinical trial. Am J Ophthalmol 146: 930-941, 2008
17. Ladas ID, Kotsolis AI, Papakostas TD, Rouvas AA, Karagiannis DA, Vergados I: Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration. Retina 27: 891-896, 2007